Cervical cancer ranks as the fourth most common cancer among women globally, with approximately 604,000 new cases in 2020. Sadly, about 90% of the estimated 342,000 cervical cancer-related deaths that same year occurred in low- and middle-income countries, highlighting an urgent need for action.
Women living with HIV face a sixfold higher risk of cervical cancer, accounting for roughly 5% of all cases. This heightened risk, affecting younger women worldwide, transcends borders.
High-income nations have established robust programs, including HPV vaccinations and regular screenings, enabling early detection and effective management of pre-cancerous lesions.
Conversely, low- and middle-income countries struggle with limited access to prevention measures, leading to delayed diagnoses, advanced disease stages, and restricted access to vital treatments like surgery and chemotherapy.
The global mortality rate for cervical cancer, at 13.3 per 100,000 women in 2020 (age-standardized rate), can significantly decrease with effective interventions. Addressing these disparities and expanding access to prevention and treatment are crucial in the global fight against cervical cancer.